CD4 and inflammatory bowel disease: Inhibition of ROCK2 remarkably decreases the percentage of IFN-γ+CD4+T cells and IL-17A+CD4+T cells, and increases the percentage of Foxp3+CD4+T cells in inflammatory bowel disease [19].